222 related articles for article (PubMed ID: 19671047)
1. HIF-1 inhibitors for cancer therapy: from gene expression to drug discovery.
Semenza GL
Curr Pharm Des; 2009; 15(33):3839-43. PubMed ID: 19671047
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of HIF-1 inhibitors as anticancer agents.
Semenza GL
Drug Discov Today; 2007 Oct; 12(19-20):853-9. PubMed ID: 17933687
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors.
Xia Y; Choi HK; Lee K
Eur J Med Chem; 2012 Mar; 49():24-40. PubMed ID: 22305612
[TBL] [Abstract][Full Text] [Related]
4. Cancer therapeutic agents targeting hypoxia-inducible factor-1.
Wang R; Zhou S; Li S
Curr Med Chem; 2011; 18(21):3168-89. PubMed ID: 21671859
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-inducible factor-1 in human breast and prostate cancer.
Kimbro KS; Simons JW
Endocr Relat Cancer; 2006 Sep; 13(3):739-49. PubMed ID: 16954428
[TBL] [Abstract][Full Text] [Related]
6. Gefitinib circumvents hypoxia-induced drug resistance by the modulation of HIF-1alpha.
Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Kim CH; Yoo YD; Lee JC
Oncol Rep; 2009 Mar; 21(3):801-7. PubMed ID: 19212642
[TBL] [Abstract][Full Text] [Related]
7. Kamebakaurin inhibits the expression of hypoxia-inducible factor-1α and its target genes to confer antitumor activity.
Wang KS; Ma J; Mi C; Li J; Lee JJ; Jin X
Oncol Rep; 2016 Apr; 35(4):2045-52. PubMed ID: 26781327
[TBL] [Abstract][Full Text] [Related]
8. Role of hypoxia-inducible factor-1alpha as a cancer therapy target.
Patiar S; Harris AL
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S61-75. PubMed ID: 17259560
[TBL] [Abstract][Full Text] [Related]
9. SENP1 desensitizes hypoxic ovarian cancer cells to cisplatin by up-regulating HIF-1α.
Ao Q; Su W; Guo S; Cai L; Huang L
Sci Rep; 2015 Nov; 5():16396. PubMed ID: 26548925
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways.
Rohwer N; Cramer T
Drug Resist Updat; 2011 Jun; 14(3):191-201. PubMed ID: 21466972
[TBL] [Abstract][Full Text] [Related]
11. Bridging hypoxia, inflammation and estrogen receptors in thyroid cancer progression.
Tafani M; De Santis E; Coppola L; Perrone GA; Carnevale I; Russo A; Pucci B; Carpi A; Bizzarri M; Russo MA
Biomed Pharmacother; 2014 Feb; 68(1):1-5. PubMed ID: 24286852
[TBL] [Abstract][Full Text] [Related]
12. Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1.
Brown LM; Cowen RL; Debray C; Eustace A; Erler JT; Sheppard FC; Parker CA; Stratford IJ; Williams KJ
Mol Pharmacol; 2006 Feb; 69(2):411-8. PubMed ID: 16254058
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-inducible factor-1alpha expression predicts the response to 5-fluorouracil-based adjuvant chemotherapy in advanced gastric cancer.
Nakamura J; Kitajima Y; Kai K; Mitsuno M; Ide T; Hashiguchi K; Hiraki M; Miyazaki K
Oncol Rep; 2009 Oct; 22(4):693-9. PubMed ID: 19724845
[TBL] [Abstract][Full Text] [Related]
14. An Akt/hypoxia-inducible factor-1alpha/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells.
Lau CK; Yang ZF; Ho DW; Ng MN; Yeoh GC; Poon RT; Fan ST
Clin Cancer Res; 2009 May; 15(10):3462-71. PubMed ID: 19447872
[TBL] [Abstract][Full Text] [Related]
15. Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells.
Manohar SM; Padgaonkar AA; Jalota-Badhwar A; Rao SV; Joshi KS
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):15-27. PubMed ID: 22083267
[TBL] [Abstract][Full Text] [Related]
16. Involvement of hypoxia-inducible factor 1 in human cancer.
Semenza GL
Intern Med; 2002 Feb; 41(2):79-83. PubMed ID: 11868612
[TBL] [Abstract][Full Text] [Related]
17. LW6, a novel HIF-1 inhibitor, promotes proteasomal degradation of HIF-1alpha via upregulation of VHL in a colon cancer cell line.
Lee K; Kang JE; Park SK; Jin Y; Chung KS; Kim HM; Lee K; Kang MR; Lee MK; Song KB; Yang EG; Lee JJ; Won M
Biochem Pharmacol; 2010 Oct; 80(7):982-9. PubMed ID: 20599784
[TBL] [Abstract][Full Text] [Related]
18. Recent agents targeting HIF-1α for cancer therapy.
Hu Y; Liu J; Huang H
J Cell Biochem; 2013 Mar; 114(3):498-509. PubMed ID: 22961911
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1α, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation.
Long Y; Tsai WB; Chang JT; Estecio M; Wangpaichitr M; Savaraj N; Feun LG; Chen HH; Kuo MT
Oncotarget; 2016 Dec; 7(50):82658-82670. PubMed ID: 27765932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
